Evidence map›Paper›PMID 25768835›Full record

Observational studyAIDS (London, England)2015

Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care.

Gary Marks, Lytt I Gardner, Charles E Rose, Anne Zinski, Richard D Moore, Susan Holman, Allan E Rodriguez, Meg Sullivan, Thomas P Giordano

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in AIDS (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Longitudinal analysis of HIV outcomes for persons living with HIV in non-urban areas in southern Alberta, Canada.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gary MarksaDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia bDepartment of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama cDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland dState University of New York, Downstate Medical Center, Brooklyn, New York eDivision of Infectious Diseases, Miller School of Medicine, University of Miami, Florida fDepartment of Medicine, Boston University School of Medicine, Boston, Massachusetts gDepartment of Medicine, Baylor College of Medicine, and the Center for Innovations in Quality, Effectiveness and Safety, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
Lytt I Gardner
Charles E Rose
Anne Zinski
Richard D Moore
Susan Holman
Allan E Rodriguez
Meg Sullivan
Thomas P Giordano

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ALLAN E RODRIGUEZ · 2007 to 2026
$33.8M
Virology CoreP30AI036211 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI BUTEL, JANET S · 1994 to 2015
$21.7M
NIAID NIH HHS P30 AI036211NIAID NIH HHS P30 AI073961NIAID NIH HHS P30 AI094189
6 · The paper itself

Abstract

objectiveWe examined HIV transmission potential of patients in care by analyzing the amount of person-time spent above a viral load threshold that increases risk for transmission.

designObservational cohort and supplemental data.

methodsThe cohort included HIV patients who received care at six HIV clinics in the United States, from 1 April 2009 to 31 March 2013, and had two or more viral load tests during this interval. Person-time (in days) above a viral load of 1500 copies/ml out of the total observation time was determined by inspecting consecutive pairs of viral load results and the time intervals between those pairs. The person-time rate ratios comparing demographic and clinical subgroups were estimated with Poisson regression.

resultsThe cohort included 14 532 patients observed for a median of 1073 days with a median of nine viral load records. Ninety percent of the patients had been prescribed antiretroviral therapy. On average, viral load exceeded 1500 copies/ml during 23% of the patients' observation time (average of 84 days per year, per patient). Percentage of person-time above the threshold was higher among patients who had more than a fourth of their viral load pairs exceeding a 6-month interval (34% of observation time), patients not on antiretroviral therapy (58% of time), new/re-engaging patients (34% of time), patients 16-39 years of age (32% of time), and patients of black race (26% of time).

conclusionHIV patients in care spent an average of nearly a quarter of their time with viral loads above 1500 copies/ml, higher among some subgroups, placing them at risk for potentially transmitting HIV to others.

Indexed as

Antiretroviral Therapy, Highly ActiveViral LoadAdolescentAdultAgedAged, 80 and overCD4 Lymphocyte CountCohort StudiesFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisRegression Analysis

Identifiers

PMID25768835
PMCPMC4964849

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.